The Future of HIV/AIDS: The Road to a Cure. How HIV persists during therapy?  Ongoing viral replication occurs in subjects on suppressive HAART (TW Chun,

Slides:



Advertisements
Similar presentations
New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida.
Advertisements

Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway
Measuring the latent HIV Reservoir
The HDAC inhibitor romidepsin is safe and effectively reverses HIV-1 latency in vivo as measured by standard clinical assays Ole Schmeltz.
2014 “Towards an HIV Cure” symposium Melbourne Following in vitro culture with myeloid dendritic cells, negative regulators of T cell activation are expressed.
Unique integration patterns in an in vitro model of HIV-1 latency. Suha M. Saleh, Dimitrios Vatakis, Andrew Harman, Anthony Cunningham, Paul U. Cameron,
Contribution of the immune system to HIV persistence Sharon R Lewin Director, Infectious Disease Unit, Alfred Hospital Professor, Department of Medicine,
Short video on patients’ perspectives on cure
Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium.
Track A Report Guido Poli Vita-Salute San Raffaele University & Scientific Institute, Milano, Italy XVIII International AIDS Conference, Vienna, 2010.
Main questions on HIV persistence and on obstacles to HIV eradication Jean-Pierre Routy M.D. McGill University Montreal Toward an HIV cure: Insight into.
Instructions To use this template: –for each slide write the correct answer on the orange bar first –choose which option (A,B,C or D) and make sure you.
Controversies in HIV Cure Research Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks.
1 HIV Curative Strategies: Key Research Priorities Deeks S, et al., (2013) Nat Rev Immunol. 12(8):
Myeloid dendritic cells and HIV latency in resting T-cells Nitasha A Kumar, Vanessa A Evans, Suha Saleh, Candida de Fonseca Pereira, Paula Ellenberg, Paul.
1 Institute of Epidemiology and Infectious Diseases Research Activities The L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases Svetlana.
Alternative RNA splicing in latently infected T cells generates chimeric cellular:HIV mRNAs with the potential to generate Tat and reactivate infection.
EARLY ANTIRETROVIRAL TREATMENT HIV Cure Research Training Curriculum (CUREiculum) Early Antiretroviral (ART) Treatment Module by: Scientific Leads: Dr.
Measuring the latent HIV Reservoir
Strategies for Targeting and Eradicating the HIV Reservoir
David M. Margolis, MD Professor of Medicine Towards an HIV cure: medical, social and ethical challenges in research and testing.
2014 “Towards an HIV Cure” symposium Melbourne The Immune Checkpoints PD-1, LAG-3 and TIGIT are Biomarkers of HIV Infected Cells During ART and Identify.
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
AIDS Cure Research- Moving Into the Clinic Matt Sharp Long-term Survivor and AIDS Cure Activist San Francisco.
The role of PI3K signaling pathways in HIV-1 infection of resting CD4+T-cells Suha Saleh, Paul Cameron, Georgina Sallmann, Anthony Jaworowski, and Sharon.
Concepts in Basic Science and Translational Research
Slide 1 of 10 From DC Douek, MD, at Atlanta, GA: April 10, 2013, IAS-USA. IAS–USA Daniel C. Douek, MD, PhD Bethesda, Maryland Immune Activation, HIV Persistence,
Latent infection and cellular reservoirs
Estrogen blocks HIV re-emergence from latency and points to gender- specific differences in HIV reservoirs Jonathan Karn International AIDS Society Hammer.
HIV, CD4, and More Karen Hutcherson Jenn Mann Elizabeth McCauley Michael Powers Courtney Wilson.
IAS 2012 feedback: UK Consortium: September 2012 IAS 2012 Feedback: New findings, better drugs and the goal of a cure Simon Collins HIV.
Introduction to Basic Science Emily L. Lowe, Ph.D. Microbiology, Immunology and Molecular Genetics UCLA.
Washington D.C., USA, July 2012www.aids2012.org Viral Eradication: The Cure Agenda AIDS Research Institute (IrsiCaixa) Autonomous University of Barcelona.
Novel Approaches: Treatment and HIV Pathogenesis L. Trautmann, Ph.D. VGTI Florida.
HIV Cellular Pathogenesis III
Studies of HIV Eradication: a Case for Using NHP Models Guido Silvestri, MD Yerkes National Primate Research Center Emory University School of Medicine.
Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California,
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
11 NAPWA Symposium 6 th IAS Meeting An HIV-based Lentiviral Vector Vaccine Achieves Functional Cure Post-challenge in a Subset of Vaccinated Macaques Dr.
Has someone been cured of HIV?. Some background on HIV O Causes AIDS O Mutates rapidly O Infects T cells of the immune system O Lysogenic (can hide inside.
Are we most likely to cure HIV with gene therapy? Sharon R Lewin Director, Infectious Disease Unit, Alfred Hospital Professor, Department of Medicine,
HIV Cellular Pathogenesis III Benhur Lee, M.D.. Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load.
Learning About an HIV Cure by Doing Studies in HIV+ Subjects Alan Landay, PhD Professor and Chairman Department of Immunology/Microbiology Rush University.
Myeloid dendritic cells induce HIV-1 latency in non- proliferating CD4 + T cells IAS WORKSHOP, 16 & 17 JULY 2010.
Sporadic excesses of unintegrated HIV DNA can occur in HIV+ patients on HAART Una O’Doherty University of Pennsylvania.
HIV: Science, Sex and Society. Lecture 2. Strategies for the cure of HIV-1. Mario Stevenson, Ph.D Department of Medicine.
Mechanisms of HIV Latency
Title Box. “Towards an HIV Cure”: Presentation Outline -Why do we need a cure? -Is a cure feasible and what type of cure can we reach? -Why does HAART.
Towards an HIV Cure: Canadian Global Stakeholder’s Engagement Workshop 21 July 2015, 18h30 – 20h30 The International AIDS Society (IAS) Towards an HIV.
HBV (chronic) HIV ~400 million chronically infected
IAS Members Meeting July 19th 2011 Achievements and learning over the past 30 years: what do we need next? Françoise BARRÉ-SINOUSSI Regulation of Retroviral.
Global Advocacy “Towards an HIV Cure” Marie-Capucine Penicaud, IAS Community Scientific Literacy Workshop July 22, 2012.
HIV: Science, Sex and Society. Lecture 1. Mechanisms of viral persistence in the face of antiviral therapy. Mario Stevenson, Ph.D Department of Medicine.
Robert F. Siliciano, MD, PhD Professor of Medicine The Johns Hopkins University School of Medicine Baltimore, Maryland Update on HIV Cure Research FORMATTED:
Immune reconstitution Anjie Zhen, PhD
2014 “Towards an HIV Cure” symposium Melbourne An Overview of HIV Cure Research in 2014 Diana Finzi, Ph.D. Director, Basic Science Program Division of.
NIH HIV/AIDS Research Priorities
The impact of treatment duration on defective and expanded identical HIV genomes in T cell subsets from peripheral blood and tissues Eunok Lee.
HKU Discovers a Novel AIDS DNA Vaccine
State of HIV Cure Research
HIV Cure: Current Status and Future Perspectives
Non-ARV Based Interventions to Combat HIV/AIDS: New Insights and Initiatives Yves Lévy Inserm, VRI.
Feedback meeting September 2017
HEATHER Feedback Meeting
Aging with HIV: The NIH Research Agenda
The block-and-lock approach
Why we should ‘shock and kill’
Figure 2. Technique overview
An Integrated Overview of HIV-1 Latency
Immunologic strategies for HIV-1 remission and eradication
Presentation transcript:

The Future of HIV/AIDS: The Road to a Cure

How HIV persists during therapy?  Ongoing viral replication occurs in subjects on suppressive HAART (TW Chun, JCI; N Tobin, J Virol 2005).  HIV integrate in long lived resting memory T cells and persist despite suppressive HAART (TW Chun, Nat. Med 1995, D Finzi, Science ; TW Chun, PNAS 1997).  Reservoir cells, like other memory T cells, divide very slowly to maintain the memory of the immune system (A. Bosque and V. Planelles) T cell survival Proliferation Viral replication Courtesy of Nicholas Chomont

What is our goal? Eradication vs Remission

What strategies to control/eradicate reservoirs? 1/2  Intensification of HAART (+/- other interventions)  Early initiation of HAART (limit viral reservoirs)  Improved Drugs (penetrating anatomical compartments)  Reactivation of HIV replication from latent reservoirs:  ”Shock and Kill” HIV-induced cell death Uninfected cells Cytokines, chemical compounds… Courtesy of Nicholas Chomont

What strategies to control/eradicate reservoirs? 2/2  Interfering with immunological mechanism that contribute to HIV persistence  Other therapeutic interventions (Gene/Mol therapy, therapeutic vaccine) T cell survival Proliferation Antibodies, cytokines, gene therapy, chemotherapy Courtesy of Nicholas Chomont

While we are searching:  Keep patients ready by:  Universal Access  Early Treatment - Limit reservoirs and preserve the immune system  Invest in research:  Better understanding of biological mechanism and role of the immune system in establishing reservoirs and persistence  Better tools and models  In vitro and in vivo models  More precise assays and sensitive techniques  Drug development: increased specificity for latently infected cells  Develop translational research Inspired from Sharon Lewin

Global Scientific Strategy Towards an HIV Cure While the Global Fund keeps working towards Universal Access:  IAS to coordinate and support the creation of an international multidisciplinary scientific advisory group on HIV Reservoirs to develop a Global Scientific Strategy « Towards an HIV Cure »  A Global Scientific Consortium « Towards an (functional) HIV Cure » ?

Acknowledgements International AIDS Society, Geneva: Shirin Heidari Marie-Capucine Penicaud Tamara Torri Julie Pluies Anthony Flynn With courtesy of members of IAS Core Group Towards An HIV Cure who shared their slides: Nicolas Chomont, Vaccine and Gene Therapy Institute Florida, USA Tae-Wook Chun, National Institutes of Health, USA Sharon Lewin, Burnet Institute, Melbourne, Australia